Atlas of Clinical PET-CT in Treatment Response Evaluation in Oncology | 2021
18F-FDG PET/CT and Non 18F-FDG-PET/CT in Treatment Response Evaluation in Neuro-Oncology
Abstract
Conventional contrast-enhanced magnetic resonance imaging (CE-MRI) remains the reference standard non-invasive diagnostic tool for monitoring patients with primary and secondary brain tumours. Significant progress in the use of positron emission tomography (PET) with an array of radiotracers helps to overcome some of the limitations of CE-MRI. There has been significant development in the use of PET imaging for a number of use cases particularly in the field of neuro-oncology. In this chapter, we review examples of several PET Tracers in Treatment Response Evaluation in Neuro-oncology.